Fertility and Sterility
Volume 91, Issue 3 , Pages 694-697 , March 2009

Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: prospective randomized study

  • Ahmed Badawy, M.D.

      Affiliations

    • Department of Obstetrics & Gynecology, Mansura University, Mansoura, Egypt
    • Corresponding Author InformationReprint requests: Ahmed Badawy, M.D., Department of Obstetrics & Gynecology, Mansoura University, Gomohoreya Street, Mansoura 1223, Egypt (FAX: 0020502303939).
    • ,
  • Aboubakr Elnashar, M.D.

      Affiliations

    • Department of Obstetrics & Gynecology, Mansura University, Mansoura, Egypt
    • ,
  • Mohamed El-Ashry, M.D.

      Affiliations

    • Department of Radiotherapy & Nuclear Medicine, Benha University Hospital, Benha, Egypt
    • ,
  • May Shahat, M.D.

      Affiliations

    • Department of Radiotherapy & Nuclear Medicine, Benha University Hospital, Benha, Egypt

Received 26 October 2007 ,Revised 14 December 2007 ,Accepted 14 December 2007.

References 

  1. Muller U, Stahel A. Gonadal function after MA COP-B or VACOP-B with or without dose intensification and ABMT in young patients with aggressive non-Hodgkin's lymphoma. Ann Oncol. 1993;4:399–402
  2. Glaser SL. Reproductive factors in Hodgkin's disease in women a review. Am J Epidemiol. 1994;139:237–246
  3. Sutcliffe SB. Cytotoxic chemotherapy and gonadal function in patients with Hodgkin's disease. JAMA. 1979;242:1898–1901
  4. Shenns RJ. Gonadal dysfunction. In:  DeVita VT,  Hellman S,  Rosenberg SA editor. Cancer—principles & practice of oncology. Philadelphia: J.B. Lippincott Co.; 1993;p. 2395–2406
  5. Glode LM, Robinson J, Gould SF. Protection from cyclophosphairude induced testicular damage with an analogue of gonadotrophin-releasing hormone. Lancet. 1981;1:1132–1136
  6. Sonmezer M, Oktay K. Fertility preservation in young women undergoing breast cancer therapy. Oncologist. 2006;11:422–434
  7. Kreuser ED, Hetzel WD, Billia DO, Thiel E. Gonadal toxicity following cancer therapy in adults: significance, diagnosis, prevention and treatment. Cancer Treat Rev. 1990;17:169–175
  8. Recchia F, Sica G, De Filippis S, Saggio G, Rosselli M, Rea S. Goserelin as ovarian protection in the adjuvant treatment of premenopausal breast cancer: a phase II pilot study. Anticancer Drugs. 2002;13:417–424
  9. Blumenfeld Z, Avivi I, Linn S, Epelbaum R, Ben-Shahar M, Haim N. Prevention of irreversible chemotherapy-induced ovarian damage in young women with lymphoma by a gonadotrophin-releasing hormone agonist in parallel to chemotherapy. Hum Reprod. 1996;11:1620–1626
  10. Blumenfeld Z. Ovarian rescue/protection from chemotherapeutic agents. J Soc Gynecol Investig. 2001;8(Suppl 1):S60–S64
  11. Sklar CA, Mertens C, Mitby P, Whitton J, Stovall M, Kasper C, et al. Premature menopause in survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. J Natl Cancer Inst. 2006;98:890–896
  12. Blumenfeld Z. How to preserve fertility in young women exposed to chemotherapy? The role of GnRH agonist cotreatment in addition to cryopreservation of embrya. Oncologist. 2007;12:1044–1054
  13. Waxman JH, Ahmed R, Smith D, Wrigley PF, Gregory W, Shalet S, et al. Failure to preserve fertility in patients with Hodgkin's disease. Cancer Chemother Pharmacol. 1987;19:159–162

PII: S0015-0282(07)04330-0

doi: 10.1016/j.fertnstert.2007.12.044

Fertility and Sterility
Volume 91, Issue 3 , Pages 694-697 , March 2009

Article Tools

* Image Usage & Resolution